Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS-Symbol für "Aktive Studie, für die noch nicht rekrutiert wird"

Active, Not Recruiting

Studien-Nr. CA031-002  |   NCT03446040

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Warnsymbol
In diese Studie werden leider keine neuen Patient:innen aufgenommen, sie ist aber weiterhin aktiv.
Sie können auf die Schaltfläche "Prüfen Sie, ob eine Studie für Sie infrage kommt“ und einige Fragen zu Ihrer Gesundheit beantworten, um herauszufinden, ob eine andere Studie für Sie infrage kommt.
Kommt die Studie für Sie infrage

Zusammenfassung

  • Phase 1/Phase 2
  • Symbol für männliches und weibliches Geschlecht
  • 18+
    Altersgruppe
  • BMS-Symbol für "Aktive Studie, für die noch nicht rekrutiert wird"
    Active, Not Recruiting

Überblick

The purpose of this study is to determine whether BMS-986258 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors

Druckmedium-alt Druckmedium
email E-Mail

Wichtigste Einschlusskriterien

For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies Exclusion Criteria: - Participants with active, known or suspected autoimmune disease - Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy - Participants with other active malignancy requiring concurrent intervention - Participants with active, known or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria could apply

Behandlungsmöglichkeiten

Studienarme

ZUGEWIESENE BEHANDLUNG

Studienarme

Experimental: Arm A

ZUGEWIESENE BEHANDLUNG
  • Biological: BMS-986258

Studienarme

Experimental: Arm A1

ZUGEWIESENE BEHANDLUNG
  • Biological: BMS-986258

Studienarme

Experimental: Arm B

ZUGEWIESENE BEHANDLUNG
  • Biological: Nivolumab, BMS-986258

Studienarme

Experimental: Arm C

ZUGEWIESENE BEHANDLUNG
  • Biological: BMS-986258, Nivolumab

Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!